Spironolactone

Overview

Spironolactone, sold under the brand name Aldactone among others, is classed as a diuretic medication. It can be used to treat fluid build-up due to liver disease or kidney disease. It is also used to reduce risk of disease progression, hospitalization, and death due to some types of heart failure. Other uses include acne and excessive hair growth in women, low blood potassium that does not improve with supplementation, high blood pressure that is difficult to treat, and early puberty in boys. It is also used to block the effects of testosterone as a part of feminizing hormone therapy. Spironolactone is usually available in tablets, taken by mouth, though topical forms are also available.[1–10] WP

Common side effects include electrolyte abnormalities, particularly high blood potassium, nausea, vomiting, headache, rashes, and a decreased desire for sex. In those with liver or kidney problems, extra care should be taken.[2] WP

If taken during pregnancy, some animal studies suggest that spironolactone may affect the development of sex organs in babies. While this has not occurred in the few human studies available, women who are pregnant or considering pregnancy should discuss spironolactone use with their doctor due to the theoretical risk.[11][12][13] WP

Spironolactone is a steroid that blocks the effects of the hormones aldosterone, and to a lesser degree, testosterone, causing some estrogen-like effects. Spironolactone belongs to a class of medications known as potassium-sparing diuretics.[2][14][15][16] WP⚠ Part of this sentence could not be copied from the source. Open the source to read it in full.

Spironolactone was discovered in 1957, and was introduced in 1959. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 52nd most commonly prescribed medication in the United States, with more than 12 million prescriptions. Spironolactone has a history of use in the trans community. Its use continues despite the rise of various accessible alternatives such as bicalutamide and cyproterone acetate with more precise action and fewer side effects.[2][14][15][17–23] WP

Uses, dosage and effects

Medical uses

Spironolactone is used in the treatment of heart failure with reduced ejection fraction (HFrEF), where evidence shows that it reduces the risk of heart failure hospitalisation and mortality when added to standard therapy.[24][25][26] WP

Multiple studies show that spironolactone improves left ventricular diastolic function in patients with heart failure with preserved ejection fraction HFpEF, though without benefits in death from any cause or overall hospitalisation. One randomised controlled trial showed a modest reduction in hospitalisation due to heart failure. A secondary analysis of TOPCAT suggested possible benefit in patients with both HFpEF and resistant hypertension, but this has not been confirmed in a prospective trial designed for this subgroup. Spironolactone is an effective fourth-line add-on therapy for lowering blood pressure in resistant hypertension that remains uncontrolled despite an ACE inhibitor or ARB, calcium channel blocker, and diuretic.[27–31] WP

It is also used to treat edematous conditions such as nephrotic syndrome or ascites in people with liver disease, essential hypertension, low blood levels of potassium, secondary hyperaldosteronism (such as occurs with liver cirrhosis), and Conn's syndrome (primary hyperaldosteronism). The most common use of spironolactone is in the treatment of heart failure. On its own, spironolactone is only a weak diuretic because it primarily targets the distal nephron (collecting tubule), where only small amounts of sodium are reabsorbed, but it can be combined with other diuretics to increase efficacy. The classification of spironolactone as a "potassium-sparing diuretic" has been described as obsolete. Spironolactone is also used to treat Bartter's syndrome due to its ability to raise potassium levels.[32][33][34] WP⚠ Wikipedia itself has flagged this text: medical citation needed.

Spironolactone, which has antiandrogenic effects, may help improve acne in adult women, with modest benefits demonstrated in recent clinical trials. Its use is limited by short-term outcome data and minimal reporting of side effects. It is considered a possible alternative to antibiotics for hormonal acne. It is also used to manage other androgen-related conditions such as hirsutism, seborrhoea, and female pattern hair loss Spironolactone is used for the treatment of hirsutism in the United States. High doses of spironolactone, which are needed for considerable antiandrogenic effects, are not recommended for men due to the high risk of feminization and other side effects. Spironolactone can be used to treat symptoms of hyperandrogenism, such as due to polycystic ovary syndrome.[35–39] WP

Heart failure

Although loop diuretics help to treat acute symptoms of heart failure, mineralocorticoid receptor antagonist diuretics (such as spironolactone) can be used long-term to reduce mortality and morbidity associated with certain types of chronic heart failure. A randomized controlled trial in 1999 found that spironolactone reduced death from any cause by 30%, as well as cardiac death and heart failure hospitalisations, in patients with HFrEF on standard therapy. A 2011 randomized controlled trial found similar benefits with eplerenone in HFrEF, supporting the use of mineralocorticoid receptor antagonists in HFrEF when added to contemporary heart failure therapy. Current recommendations from the American Heart Association are to use spironolactone in patients with NYHA Class II-IV heart failure who have a left ventricular ejection fraction of less than 35%.[3][40–43] WP

Spironolactone improves left ventricular diastolic function in patients with heart failure with preserved ejection fraction, but it has no effect on mortality and hospitalization.[4][44] WP

Due to its antiandrogenic properties, spironolactone can cause effects associated with low androgen levels and hypogonadism in males. For this reason, men are typically not prescribed spironolactone for any longer than a short period of time, e.g., for an acute exacerbation of heart failure. A newer medication, eplerenone, has been approved by the US Food and Drug Administration (FDA) for the treatment of heart failure, and lacks the antiandrogenic effects of spironolactone. As such, it is far more suitable for men for whom long-term medication is being chosen. Mineralcortocoid receptor antagonists (MRA) as a class (including spironolactone, canerenone, eplerenone and finerenone) are cornerstones of heart failure with reduced ejection fraction (HFrEF EF≤40%) management, however, the comparative magnitude of effect on mortality between agents remains uncertain. Primarily, evidence explores spironolactone and eplerenone, with limited comparative data available for canerenone. Furthermore, there is limited evidence for benefit of finerenone in a HFrEF patient cohort, a newer agent recently licensed for the treatment of chronic kidney disease (CKD) in type 2 diabetes mellitus.[45][46][47] WP

High blood pressure

About one in 100 people with hypertension have elevated levels of aldosterone; in these people, the antihypertensive effect of spironolactone may exceed that of complex combined regimens of other antihypertensives since it targets the primary cause of the elevated blood pressure. Spironolactone has demonstrated consistent and clinically meaningful reductions in blood pressure when used as an add-on therapy in patients with resistant hypertension.[31][48] WP

High aldosterone levels

Spironolactone is used in the treatment of hyperaldosteronism (high aldosterone levels or mineralocorticoid excess), for instance primary aldosteronism (Conn's syndrome). Antimineralocorticoids including spironolactone and eplerenone are first-line treatments for hyperaldosteronism. They improve blood pressure and potassium levels, as well as left ventricular hypertrophy, albuminuria, and carotid intima-media thickness, in people with primary aldosteronism. In people with hyperaldosteronism due to unilateral aldosterone-producing adrenocortical adenoma, adrenalectomy should be preferred instead of antimineralocorticoids. Spironolactone should not be used to treat primary aldosteronism in pregnancy due to its antiandrogen-related risk of teratogenicity in male fetuses.[12][49–52] WP

Skin and hair conditions

Androgens such as testosterone and DHT play a critical role in the pathogenesis of a number of dermatological conditions including oily skin, acne, seborrhea, hirsutism (excessive facial/body hair growth in women), and male pattern hair loss (androgenic alopecia). In demonstration of this, women with complete androgen insensitivity syndrome do not produce sebum or develop acne and have little to no body, pubic, or axillary hair. Moreover, men with congenital 5α-reductase type II deficiency, 5α-reductase being an enzyme that greatly potentiates the androgenic effects of testosterone in the skin, have little to no acne, scanty facial hair, reduced body hair, and reportedly no incidence of male-pattern hair loss. Conversely, hyperandrogenism in women, for instance due to polycystic ovary syndrome or congenital adrenal hyperplasia, is commonly associated with acne and hirsutism, as well as virilization (masculinization) in general. In accordance with the preceding, antiandrogens are highly effective in the treatment of the aforementioned androgen-dependent skin and hair conditions.[53–63] WP

Because of the antiandrogenic activity of spironolactone, it can be quite effective in treating acne in women. In addition, spironolactone reduces oil that is naturally produced in the skin, so can be used to treat oily skin. Though not the primary intended purpose of the medication, the ability of spironolactone to be helpful with problematic skin and acne conditions was discovered to be one of the beneficial side effects and has been quite successful. Oftentimes, for women treating acne, spironolactone is prescribed and paired with a birth control pill. Positive results in the pairing of these two medications have been observed, although these results may not be seen for up to three months. Spironolactone has been reported to produce a 50 to 100% improvement in acne at sufficiently high doses. Response to treatment generally requires 1 to 3 months in the case of acne and up to 6 months in the case of hirsutism. Ongoing therapy is generally required to avoid relapse of symptoms. Spironolactone is commonly used in the treatment of hirsutism in women, and is considered to be a first-line antiandrogen for this indication. Spironolactone can be used in the treatment of female-pattern hair loss (pattern scalp hair loss in women). There is tentative low quality evidence supporting its use for this indication.[35][54][64–70] WP

Antiandrogens such as spironolactone are male-specific teratogens, which can feminize male fetuses due to their antiandrogenic effects. For this reason, antiandrogens are recommended only to be used to treat women who are of reproductive age in conjunction with adequate contraception. Oral contraceptives, which contain an estrogen and a progestin, are typically used for this purpose. Moreover, oral contraceptives themselves are functional antiandrogens and are independently effective in the treatment of androgen-dependent skin and hair conditions, hence can significantly augment the effectiveness of antiandrogens in the treatment of such conditions.[62][71][72][73] WP

Spironolactone is not generally used in men for the treatment of androgen-dependent dermatological conditions because of its feminizing side effects, but it is effective for such indications in men similarly. As an example, spironolactone has been reported to reduce symptoms of acne in males. An additional example is the usefulness of spironolactone as an antiandrogen in transgender women and nonbinary individuals.[8][9][10][69][74][75] WP

Topical spironolactone is effective in the treatment of acne, as well. As a result, topical pharmaceutical formulations containing 2 or 5% spironolactone cream became available in Italy for the treatment of acne and hirsutism in the early 1990s. The products were discontinued in 2006 when the creams were added to the list of doping substances with a decree of the Ministry of Health that year.[76][77][78] WP

Comparison

Spironolactone, the 5α-reductase inhibitor finasteride, and the nonsteroidal antiandrogen flutamide all appear to have similar effectiveness in the treatment of hirsutism. Some clinical research, though, has found that the effectiveness of spironolactone for hirsutism is greater than that of finasteride, but is less than that of flutamide. The combination of spironolactone with finasteride is more effective than either alone for hirsutism and the combination of spironolactone with a birth-control pill is more effective than a birth-control pill alone. One study showed that spironolactone or the steroidal antiandrogen cyproterone acetate both in combination with a birth-control pill had equivalent effectiveness for hirsutism. Spironolactone is considered to be a first-line treatment for hirsutism, finasteride and the steroidal antiandrogen cyproterone acetate are considered to be second-line treatments, and flutamide is no longer recommended for hirsutism due to liver toxicity concerns. The nonsteroidal antiandrogen bicalutamide is an alternative option to flutamide with improved safety.[68][79–82] WP

The combination of spironolactone with a birth-control pill in the treatment of acne appears to have similar effectiveness to a birth-control pill alone and the combination of a birth-control pill with cyproterone acetate, flutamide, or finasteride. However, this was based on low- to very low-quality evidence. Spironolactone may be more effective than birth-control pills in the treatment of acne, and the combination of spironolactone with a birth-control pill may have greater effectiveness for acne than either alone. In addition, some clinical research has found that flutamide is more effective than spironolactone in the treatment of acne. In one study, flutamide decreased acne scores by 80% within 3 months, whereas spironolactone decreased symptoms by only 40% in the same period. However, the use of flutamide for acne is limited by its liver toxicity. Bicalutamide is a potential alternative to flutamide for acne as well. Spironolactone can be considered as a first-line treatment for acne in those who have failed other standard treatments such as topical therapies and under certain other circumstances, although this is controversial due to the side effects of spironolactone and its teratogenicity.[63][65][83–92] WP

Insufficient clinical evidence exists to compare the effectiveness of spironolactone with other antiandrogens for female-pattern hair loss. The effectiveness of spironolactone in the treatment of both acne and hirsutism appears to be dose-dependent, with higher doses being more effective than lower doses. Higher doses also have greater side effects, such as menstrual irregularities.[65][83][93][94][95] WP

Transgender hormone therapy

Spironolactone is widely used as an antiandrogen in feminizing hormone therapy for transfeminine people and is recommended by transgender medicine clinical guidelines for such purposes. It is the most commonly used antiandrogen in transfeminine people in the United States, whereas cyproterone acetate (CPA), which is not available in the United States, is widely used in Europe and throughout the rest of the world. Spironolactone is inferior to CPA, other progestogens, GnRH modulators, and high-dose parenteral estradiol monotherapy in terms of achieving adequate testosterone suppression in transfeminine people. However, spironolactone acts as a direct though weak androgen receptor antagonist rather than by suppressing testosterone levels, and hence its antiandrogenic effects and potential therapeutic benefits in this context are not necessarily reflected in testosterone levels. In any case, while widely used, there remain very limited comparative clinical data on spironolactone versus other antiandrogenic approaches in terms of physical feminization outcomes in transfeminine people.[8][9][10][96–100] WP

Forms

Spironolactone is available in the form of tablets (25, 50, and 100 mg; brand name Aldactone, others) and suspensions (25 mg/5 mL; brand name Carospir) for oral administration. It had also been marketed in the form of 2 or 5% topical cream in Italy for the treatment of acne and hirsutism under the brand name Spiroderm, but this product is no longer available. The medication is also available in combination with other medications, such as hydrochlorothiazide (brand name Aldactazide, others). Spironolactone has poor water solubility, so only oral and topical formulations have been developed; other routes of administration such as intravenous injection are not used. The only antimineralocorticoid that is available as a solution for parenteral use is the related medication potassium canrenoate.[101–110] WP⚠ Wikipedia itself has flagged this text: failed verification.

Risks and side effects

Contraindications

Contraindications of spironolactone include hyperkalemia (high potassium levels), severe and end-stage kidney disease (due to high hyperkalemia risk, except possibly in those on dialysis), Addison's disease (adrenal insufficiency and low aldosterone levels), and concomitant use of eplerenone. It should also be used with caution in people with certain neurological disorders, as well as those who experience or have experienced anuria (lack of urine production), acute kidney injury, or significant impairment of kidney excretory function with risk of hyperkalemia.[111][112] WP

Side effects

One of the most common side effects of spironolactone is frequent urination. Other general side effects include dehydration, hyponatremia (low sodium levels), mild hypotension, ataxia (muscle incoordination), drowsiness, dizziness, dry skin, and rashes. Because of its antiandrogenic activity, spironolactone can cause breast tenderness, gynecomastia (breast development), feminization in general, and demasculinization, as well as sexual dysfunction including loss of libido and erectile dysfunction, although these side effects are usually confined to high doses. At very high doses (400 mg/day), spironolactone has also been associated with testicular atrophy and reversibly reduced fertility, including semen abnormalities, such as decreased sperm count and motility in men, but such doses of spironolactone are rarely used clinically. In women, spironolactone can cause menstrual irregularities, breast tenderness, and breast enlargement. Aside from these adverse effects, the side effects of spironolactone in women taking high doses are minimal, and it is well tolerated.[37][65][84][113–117] WP

A potential side effect of spironolactone is hyperkalemia (high potassium levels), which in severe cases, can be life-threatening. Hyperkalemia can present as a normal anion-gap metabolic acidosis. The addition of spironolactone to loop diuretics in people with heart failure reportedly was associated with a higher risk of hyperkalemia and acute kidney injury. Spironolactone may put people at a heightened risk for gastrointestinal issues such as nausea, vomiting, diarrhea, cramping, and gastritis. In addition, some evidence suggests an association between use of the medication and bleeding from the stomach and duodenum, though a causal relationship between the two has not been established. Also, spironolactone is immunosuppressive in the treatment of sarcoidosis.[111][118–122] WP

Most of the side effects of spironolactone are dose-dependent. Low-dose spironolactone is generally very well tolerated. Even higher doses of spironolactone, such as 100 mg/day, are well tolerated in most individuals. Dose-dependent side effects of spironolactone include menstrual irregularities, breast tenderness, and enlargement, orthostatic hypotension, and hyperkalemia. Its side effects are usually mild and rarely result in discontinuation.[64] WP

High potassium levels

Spironolactone can cause high blood potassium levels. Rarely, this can be fatal. Of people with heart disease prescribed typical dosages of spironolactone, 10 to 15% develop some degree of hyperkalemia, and 6% develop severe hyperkalemia. At a higher dosage, a rate of hyperkalemia of 24% has been observed. An abrupt and major increase in the rate of hospitalization due to hyperkalemia from 0.2 to 11% and in the rate of death due to hyperkalemia from 0.3 to 2.0 per 1,000 between early 1994 and late 2001 has been attributed to a parallel rise in the number of prescriptions written for spironolactone upon the publication of the Randomized Aldactone Evaluation Study (RALES) in July 1999. However, another population-based study in Scotland failed to replicate these findings. The risk of hyperkalemia with spironolactone is greatest in the elderly, in people with renal impairment (e.g., due to chronic kidney disease or diabetic nephropathy), in people taking certain other medications (including ACE (angiotensin-converting-enzyme) inhibitors, angiotensin II receptor blockers, nonsteroidal anti-inflammatory drugs, the antibiotic trimethoprim, and potassium supplements), and at higher dosages of spironolactone.[32][115][123–128] WP

Although spironolactone poses an important risk of hyperkalemia in the elderly, in those with kidney or cardiovascular disease, and/or in those taking medications or supplements, which increase circulating potassium levels, a large retrospective study found that the rate of hyperkalemia in young women without such characteristics who had been treated with high doses of spironolactone for dermatological conditions did not differ from those of controls. This was the conclusion of a 2017 hybrid systematic review of studies of spironolactone for acne in women, as well, which found that hyperkalemia was rare and was invariably mild and clinically insignificant. These findings suggest that hyperkalemia may not be a significant risk in such individuals, and that routine monitoring of circulating potassium levels may be unnecessary in this population. Other sources have claimed that hyperkalemia can nonetheless also occur in people with more normal renal function and presumably without such risk factors. Occasional testing on a case-by-case basis in those with known risk factors may be justified. Side effects of spironolactone that may be indicative of hyperkalemia and if persistent could justify serum potassium testing include nausea, fatigue, and particularly muscle weakness. Notably, reduced or no routine potassium monitoring with spironolactone in young women would reduce costs associated with its use.[32][65][66][129] WP

Among young, gender-diverse individuals taking spironolactone, hyperkalemia is rare and (if present) transient and asymptomatic. Larger doses do not appear to increase risks in this population. A broader retrospective study found that the rate of hyperkalemia in gender-diverse individuals is correlated with age, with those above 45 years old being more at risk. The finding suggests that patients below or at 45 years old without other conditions that affect potassium handling can be spared from routine monitoring.[130][131] WP

Breast changes

Spironolactone can cause breast pain and enlargement in women. This is "probably because of estrogenic effects on target tissue." At low doses, breast tenderness has been reported in only 5% of women, but at high doses, it has been reported in up to 40% of women. Breast enlargement and tenderness may occur in 26% of women at high doses. Some women regard spironolactone-induced breast enlargement as a positive effect.[64][65][84][115][132][133][134] WP

Spironolactone also commonly and dose-dependently produces gynecomastia (breast development) as a side effect in men. At low doses, the rate is only 5 to 10%, but at high doses, up to or exceeding 50% of men may develop gynecomastia. In the RALES, 9.1% of men taking 25 mg/day spironolactone developed gynecomastia, compared to 1.3% of controls. Conversely, in studies of healthy men given high-dose spironolactone, gynecomastia occurred in 3 of 10 (30%) at 100 mg/day, in 5 of 8 (62.5%) at 200 mg/day, and in 6 of 9 (66.7%) at 400 mg/day, relative to none of 12 controls. The severity of gynecomastia with spironolactone varies considerably, but is usually mild. As with breast enlargement caused by spironolactone in women, gynecomastia due to spironolactone in men is often, although inconsistently, accompanied by breast tenderness. In the RALES, only 1.7% of men developed breast pain, relative to 0.1% of controls.[114][133][135–139] WP

The time to onset of spironolactone-induced gynecomastia has been found to be 27 ± 20 months at low doses and 9 ± 12 months at high doses. Gynecomastia induced by spironolactone usually regresses after a few weeks following discontinuation of the medication. However, after a sufficient duration of gynecomastia being present (e.g., one year), hyalinization and fibrosis of the tissue occurs and drug-induced gynecomastia may become irreversible.[114][137][140][141] WP

Menstrual disturbances

Spironolactone at higher doses can cause menstrual irregularities as a side effect in women, including metrorrhagia (intermenstrual bleeding), amenorrhea (absence of menstruation), and breakthrough bleeding. They are common during spironolactone therapy, with 10 to 50% of women experiencing them at moderate doses and almost all experiencing them at a high doses. For example, about 20% of women experienced menstrual irregularities with 50 to 100 mg/day spironolactone, whereas about 70% experienced menstrual irregularities at 200 mg/day. Most women taking moderate doses of spironolactone develop amenorrhea, and normal menstruation usually returns within two months of discontinuation. Spironolactone produces an irregular and anovulatory pattern of menstrual cycles. It is also associated with metrorrhagia and menorrhagia (heavy menstrual bleeding) in large percentages of women, as well as with polymenorrhea (short menstrual cycles). The medication reportedly has no birth control effect.[64][84][115][132][142][143][144] WP

The weak progestogenic activity of spironolactone has been suggested to be responsible for these effects, although not established, and spironolactone has been shown to possess insignificant progestogenic and antiprogestogenic activity even at high dosages in women. An alternative proposed cause is inhibition of 17α-hydroxylase and hence sex steroid metabolism by spironolactone and consequent changes in sex hormone levels. Indeed, CYP17A1 genotype is associated with polymenorrhea. Regardless of their mechanism, the menstrual disturbances associated with spironolactone can usually be controlled well by concomitant treatment with a birth-control pill, due to the progestin component.[84][114][145–148] WP

Mood changes

Research is mixed on whether antimineralocorticoids such as spironolactone have positive or negative effects on mood. In any case, spironolactone might have the capacity to increase the risk of depressive symptoms. However, a 2017 hybrid systematic review found that the incidence of depression in women treated with spironolactone for acne was less than 1%. Likewise, a 10-year observational study found that the incidence of depression in 196 transgender women taking high-dose spironolactone in combination with an estrogen was less than 1%.[65][149–152] WP

Lipid changes

Spironolactone has been found to increase LDL ("bad") cholesterol and decrease HDL ("good") cholesterol levels at the relatively high doses used in women with polycystic ovary syndrome. As such, it may have unfavorable effects on the blood lipid profile in this context. Heightened LDL cholesterol levels are a potential risk factor for cardiovascular disease, such as atherosclerosis or coronary heart disease. Consequently, spironolactone probably should not be given to women with dyslipidemia (e.g., high cholesterol). Unfavorable lipid changes have also been seen with other antiandrogens, such as cyproterone acetate and bicalutamide.[8][82][153–157] WP

Rare reactions

Aside from hyperkalemia, spironolactone may rarely cause adverse reactions such as anaphylaxis, kidney failure, hepatitis (two reported cases, neither serious), agranulocytosis, DRESS syndrome, Stevens–Johnson syndrome, or toxic epidermal necrolysis. Five cases of breast cancer in patients who took spironolactone for prolonged periods of time have been reported.[115][136][158–161] WP

Spironolactone bodies

Long-term administration of spironolactone gives the histologic characteristic of "spironolactone bodies" in the adrenal cortex, which are eosinophilic, round, concentrically laminated cytoplasmic inclusions surrounded by clear halos in preparations stained with hematoxylin and eosin.[162] WP

Pregnancy and breastfeeding

Spironolactone can cross the placenta. It has been found in the breast milk of lactating mothers, but only very small amounts of spironolactone and its metabolite canrenone enter breast milk, and the amount received by an infant during breastfeeding (<0.5% of the mother's dose) is considered to be insignificant.[111][132][163] WP

A study found that spironolactone was not associated with teratogenicity in the offspring of rats. Because it is an antiandrogen, however, spironolactone could theoretically have the potential to cause feminization of male fetuses at sufficient doses. In accordance, a subsequent study found that partial feminization of the genitalia occurred in the male offspring of rats that received doses of spironolactone that were five times higher than those normally used in humans (200 mg/kg per day). Another study found permanent, dose-related reproductive tract abnormalities rat offspring of both sexes at lower doses (50 to 100 mg/kg per day).[164][165][166] WP

In practice however, although experience is limited, spironolactone has never been reported to cause observable feminization or any other congenital defects in humans. Among 31 human newborns exposed to spironolactone in the first trimester, no signs of any specific birth defects were seen. A case report described a woman who was prescribed spironolactone during pregnancy with triplets and delivered all three (one boy and two girls) healthy; no observable feminization occurred in the boy. In addition, spironolactone has been used at high doses to treat pregnant women with Bartter's syndrome, and none of the infants (three boys, two girls) showed toxicity, including feminization in the male infants. Similar findings, albeit also limited, exist for another antiandrogen, cyproterone acetate (prominent genital defects in male rats, but no human abnormalities (including feminization of male fetuses) at both a low dose of 2 mg/day or high doses of 50 to 100 mg/day). In any case, spironolactone is nonetheless not recommended during pregnancy due to theoretical concerns relating to feminization of males and also to potential alteration of fetal potassium levels.[163][164][165][167][168][169] WP

A 2019 systematic review found insufficient evidence that spironolactone causes birth defects in humans. Evidence was insufficient to be certain that it does not.[11] WP

Overdose

Spironolactone is relatively safe in acute overdose. Symptoms following an acute overdose of spironolactone may include drowsiness, confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, and diarrhea. In rare cases, hyponatremia, hyperkalemia, or hepatic coma may occur in individuals with severe liver disease. These adverse reactions are unlikely, though, in the event of an acute overdose. Hyperkalemia can occur following an overdose of spironolactone, and this is especially so in people with decreased kidney function. Spironolactone has been studied at extremely high oral doses of up to 2,400 mg per day in clinical trials. Its oral median lethal dose (LD₅₀) is more than 1,000 mg/kg in mice, rats, and rabbits.[110][111][170] WP

No specific antidote for overdose of spironolactone is known. Treatment may consist of induction of vomiting or stomach evacuation by gastric lavage. The treatment of spironolactone overdose is supportive, with the purpose of maintaining hydration, electrolyte balance, and vital functions. Spironolactone should be discontinued in people with impaired kidney function or hyperkalemia.[111] WP

Interactions

Interactions

Spironolactone often increases serum potassium levels and can cause hyperkalemia, a very serious condition. Therefore, people using this medication should avoid potassium supplements and salt substitutes containing potassium. Physicians must be careful to monitor potassium levels in both males and females who are taking spironolactone as a diuretic, especially during the first 12 months of use and whenever the dosage is increased. Doctors may also recommend that some patients may be advised to limit dietary consumption of potassium-rich foods. Recent data suggest that both potassium monitoring and dietary restriction of potassium intake are unnecessary in healthy young women taking spironolactone for acne and in healthy, young, gender-diverse individuals taking spironolactone for hormone therapy. Spironolactone together with trimethoprim/sulfamethoxazole increases the likelihood of hyperkalemia, especially in the elderly. The trimethoprim portion acts to prevent potassium excretion in the distal tubule of the nephron.[129][131][171][172] WP

Spironolactone has been reported to induce the enzymes CYP3A4 and certain UDP-glucuronosyltransferases, which can result in interactions with various medications. However, metabolites of spironolactone reportedly irreversibly inhibit CYP3A4. In any case, spironolactone has been found to reduce the bioavailability of oral estradiol, which could be due to induction of estradiol metabolism via CYP3A4. Spironolactone has also been found to inhibit UGT2B7. Spironolactone can also have numerous other interactions, most commonly with other cardiac and blood-pressure medications, for instance digoxin.[111][173–178] WP

Licorice, which has indirect mineralocorticoid activity by inhibiting mineralocorticoid metabolism, has been found to inhibit the antimineralocorticoid effects of spironolactone. Moreover, the addition of licorice to spironolactone has been found to reduce the antimineralocorticoid side effects of spironolactone in women treated with it for hyperandrogenism, and licorice hence may be used to reduce these side effects in women treated with spironolactone as an antiandrogen who are bothered by them. Conversely, spironolactone is useful in reversing licorice-induced hypokalemia. Aspirin and other NSAIDs have been found to attenuate the diuresis and natriuresis induced by spironolactone, but not to affect its antihypertensive effect.[34][179–184] WP

Some research has suggested that spironolactone might be able to interfere with the effectiveness of antidepressant treatment. As the medication acts as an antimineralocorticoid, it might be able to reduce the effectiveness of certain antidepressants by interfering with normalization of the hypothalamic–pituitary–adrenal axis and by increasing levels of glucocorticoids such as cortisol. Other research contradicts this hypothesis and has suggested that spironolactone might produce antidepressant effect, for instance, in studies showing antidepressant-like effects of spironolactone in animals.[185][186][187] WP

Pharmacology

Pharmacodynamics

The pharmacodynamics of spironolactone are characterized by high antimineralocorticoid activity, moderate antiandrogenic activity, and weak steroidogenesis inhibition, among other more minor activities. Spironolactone is a prodrug, so most of its actions are actually mediated by its various active metabolites. The major active forms of spironolactone are 7α-thiomethylspironolactone (7α-TMS) and canrenone (7α-desthioacetyl-δ⁶-spironolactone).[109][110][113][138] WP

Spironolactone is a potent antimineralocorticoid. That is, it is an antagonist of the mineralocorticoid receptor (MR), the biological target of mineralocorticoids like aldosterone and 11-deoxycorticosterone. By blocking the MR, spironolactone inhibits the effects of mineralocorticoids in the body. The antimineralocorticoid activity of spironolactone is responsible for its therapeutic efficacy in the treatment of edema, high blood pressure, heart failure, hyperaldosteronism, and ascites due to cirrhosis. It is also responsible for many of the side effects of spironolactone, such as urinary frequency, dehydration, hyponatremia, low blood pressure, fatigue, dizziness, metabolic acidosis, decreased kidney function, and its risk of hyperkalemia. Due to the antimineralocorticoid activity of spironolactone, levels of aldosterone are significantly increased by the medication, probably reflecting an attempt of the body to maintain homeostasis.[62][84][109][188][189][190] WP

Spironolactone is a moderate antiandrogen. That is, it is an antagonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT). By blocking the AR, spironolactone inhibits the effects of androgens in the body. The antiandrogenic activity of spironolactone is mainly responsible for its therapeutic efficacy in the treatment of androgen-dependent skin and hair conditions like acne, seborrhea, hirsutism, and pattern hair loss and hyperandrogenism in women, precocious puberty in boys with testotoxicosis, and as a component of feminizing hormone therapy for transgender women. It is also primarily responsible for some of its side effects, like breast tenderness, gynecomastia, feminization, and demasculinization in men. Blockade of androgen signaling in the breast disinhibits the actions of estrogens in this tissue. Although useful as an antiandrogen in women, who have low testosterone levels compared to men, spironolactone is described as having relatively weak antiandrogenic activity.[113][114][145][175][177][191–197] WP

Spironolactone is a weak steroidogenesis inhibitor. That is, it inhibits steroidogenic enzymes, or enzymes involved in the production of steroid hormones. Spironolactone and/or its metabolites have been found in vitro to weakly inhibit a broad array of steroidogenic enzymes including cholesterol side-chain cleavage enzyme, 17α-hydroxylase, 17,20-lyase, 5α-reductase, 3β-hydroxysteroid dehydrogenase, 11β-hydroxylase, 21-hydroxylase, and aldosterone synthase (18-hydroxylase). However, although very high doses of spironolactone can considerably decrease steroid hormone levels in animals, spironolactone has shown mixed and inconsistent effects on steroid hormone levels in clinical studies, even at high clinical doses. In any case, the levels of most steroid hormones, including testosterone and cortisol, are usually unchanged by spironolactone in humans, which may in part be related to compensatory upregulation of their synthesis. The weak steroidogenesis inhibition of spironolactone might contribute to its antiandrogenic efficacy to some degree and may explain its side effect of menstrual irregularities in women. However, its androgen synthesis inhibition is probably clinically insignificant.[65][67][113][114][138][145][175][198–201] WP

Spironolactone has been found in some studies to increase levels of estradiol, an estrogen, although many other studies have found no changes in estradiol levels. The mechanism of how spironolactone increases estradiol levels is unclear, but it may involve inhibition of the inactivation of estradiol into estrone and enhancement of the peripheral conversion of testosterone into estradiol. It is notable that spironolactone has been found in vitro to act as a weak inhibitor of 17β-hydroxysteroid dehydrogenase 2, an enzyme that is involved in the conversion of estradiol into estrone. Increased levels of estradiol with spironolactone may be involved in its preservation of bone density and in its side effects such as breast tenderness, breast enlargement, and gynecomastia in women and men.[113][138][202–207] WP

In response to the antimineralocorticoid activity spironolactone, and in an attempt to maintain homeostasis, the body increases aldosterone production in the adrenal cortex. Some studies have found that levels of cortisol, a glucocorticoid hormone that is also produced in the adrenal cortex, are increased as well. Spironolactone "acts at the basolateral side of the upper-distal tubule as well as in the collecting tubule," and does not have glucocorticoid-like effects at these specific sites; it can sometimes be prescribed as an alternative to glucocorticoids for patients with Glucocorticoid-Remediable Aldosteronism characterized by aldosterone excess, In patients "receiving spironolactone, there was a significant positive correlation between the change in cortisol and the change in HbA1c (r = 0.489, P =.003)." Patients taking spironolactone must be monitored for side effects including dizziness, headache, fatigue, diarrhea, hypertriglyceridemia and elevated liver enzymes.[95][145][208–216] WP

Other activities of spironolactone may include very weak interactions with the estrogen and progesterone receptors and agonism of the pregnane X receptor. These activities could contribute to the menstrual irregularities and breast side effects of spironolactone and to its drug interactions, respectively.[33][95][217][218][219] WP

Pharmacokinetics

The pharmacokinetics of spironolactone have not been studied well, which is in part because it is an old medication that was developed in the 1950s. Nonetheless, much has been elucidated about the pharmacokinetics of spironolactone over the decades.[109][139][220–226] WP

Absorption

The bioavailability of spironolactone when taken by mouth is 60 to 90%. The bioavailability of spironolactone and its metabolites increases significantly (+22–95% increases in levels) when spironolactone is taken with food, although it is uncertain whether this further increases the therapeutic effects of the medication. The increase in bioavailability is thought to be due to promotion of the gastric dissolution and absorption of spironolactone, as well as due to a decrease of the first-pass metabolism. The relationship between a single dose of spironolactone and plasma levels of canrenone, a major active metabolite of spironolactone, has been found to be linear across a dose range of 25 to 200 mg spironolactone. Steady-state concentrations of spironolactone are achieved within 8 to 10 days of treatment initiation.[109][195][227–235] WP

Little or no systemic absorption has been observed with topical spironolactone.[236] WP

Distribution

Spironolactone and its metabolite canrenone are highly plasma protein bound, with percentages of 88.0% and 99.2%, respectively. Spironolactone is bound equivalently to albumin and α₁-acid glycoprotein, while canrenone is bound only to albumin. Spironolactone and its metabolite 7α-thiospironolactone show very low or negligible affinity for sex hormone-binding globulin (SHBG). In accordance, a study of high-dosage spironolactone treatment found no change in steroid binding capacity related to SHBG or to corticosteroid-binding globulin (CBG), suggesting that spironolactone does not displace steroid hormones from their carrier proteins. This is in contradiction with widespread statements that spironolactone increases free estradiol levels by displacing estradiol from SHBG.[95][109][237–241] WP

Spironolactone appears to cross the blood–brain barrier.[242][243] WP

Metabolism

Spironolactone is rapidly and extensively metabolized in the liver upon oral administration and has a very short terminal half-life of 1.4 hours. The major metabolites of spironolactone are 7α-thiomethylspironolactone (7α-TMS), 6β-hydroxy-7α-thiomethylspironolactone (6β-OH-7α-TMS), and canrenone (7α-desthioacetyl-δ⁶-spironolactone). These metabolites have much longer elimination half-lives than spironolactone of 13.8 hours, 15.0 hours, and 16.5 hours, respectively, and are responsible for the therapeutic effects of the medication. As such, spironolactone is a prodrug. The 7α-thiomethylated metabolites of spironolactone were not known for many years and it was originally thought that canrenone was the major active metabolite of the medication, but subsequent research identified 7α-TMS as the major metabolite. Other known but more minor metabolites of spironolactone include 7α-thiospironolactone (7α-TS), which is an important intermediate to the major metabolites of spironolactone, as well as the 7α-methyl ethyl ester of spironolactone and the 6β-hydroxy-7α-methyl ethyl ester of spironolactone.[109][173][227][234][244][245][246] WP

Spironolactone is hydrolyzed or deacetylated at the thioester of the C7α position into 7α-TS by carboxylesterases. Following formation of 7α-TS, it is S-oxygenated by flavin-containing monooxygenases to form an electrophilic sulfenic acid metabolite. This metabolite is involved in the CYP450 inhibition of spironolactone, and also binds covalently to other proteins. 7α-TS is also S-methylated into 7α-TMS, a transformation catalyzed by thiol S-methyltransferase. Unlike the related medication eplerenone, spironolactone is said to not be metabolized by CYP3A4. However, hepatic CYP3A4 is likely responsible for the 6β-hydroxylation of 7α-TMS into 6β-OH-7α-TMS. 7α-TMS may also be hydroxylated at the C3α and C3β positions. Spironolactone is dethioacetylated into canrenone. Finally, the C17 γ-lactone ring of spironolactone is hydrolyzed by the paraoxonase PON3. It was originally thought to be hydrolyzed by PON1, but this was due to contamination with PON3.[173][247–254] WP

Elimination

The majority of spironolactone is eliminated by the kidneys, while minimal amounts are handled by biliary excretion.[255] WP

Research

Prostate conditions

Spironolactone has been studied at a high dosage in the treatment of benign prostatic hyperplasia (BPH; enlarged prostate). It was found to be better than placebo in terms of symptom relief following three months of treatment. However, this was not maintained after six months of treatment, by which point the improvements had largely disappeared. Moreover, no difference was observed between spironolactone and placebo with regard to volume of residual urine or prostate size. Gynecomastia was observed in about 5% of people. On the basis of these results, it has been said that spironolactone has no place in the treatment of BPH.[256][257][258] WP

Spironolactone has been studied and used limitedly in the treatment of prostate cancer.[34][259][260] WP

Epstein–barr virus

Spironolactone has been found to block Epstein–Barr virus (EBV) production and that of other human herpesviruses by inhibiting the function of an EBV protein SM, which is essential for infectious virus production. This effect of spironolactone was determined to be independent of its antimineralocorticoid actions.[261] WP

Other conditions

Spironolactone has been studied in the treatment of rosacea in both males and females.[74][262–265] WP

Spironolactone has been studied in fibromyalgia in women. It has also been studied in bulimia nervosa in women, but was not found to be effective.[266][267][268] WP

History

History

The natriuretic effects of progesterone were demonstrated in 1955, and the development of spironolactone as a synthetic antimineralocorticoid analogue of progesterone shortly followed this. Spironolactone was first synthesized in 1957, was patented between 1958 and 1961, and was first marketed, as an antimineralocorticoid, in 1959. Gynecomastia was first reported with spironolactone in 1962, and the antiandrogenic activity of the medication was first described in 1969. This shortly followed the discovery in 1967 that gynecomastia is an important and major side effect of AR antagonists. Spironolactone was first studied in the treatment of hirsutism in women in 1978. It has since become the most widely used antiandrogen for dermatological indications in women in the United States. Spironolactone was first studied as an antiandrogen in transgender women in 1986, and has since become widely adopted for this purpose as well, particularly in the United States where cyproterone acetate is not available.[17][18][104][110][137][179][269–288] WP

Early oral spironolactone tablets showed poor absorption. The formulation was eventually changed to a micronized formulation with particle sizes of less than 50 μg, which resulted in approximately 4-fold increased potency.[289][290] WP

Legal status

Generic names

The English, French, and generic name of the medication is spironolactone and this is its INN (International Nonproprietary Name), USAN (United States Adopted Name), USP (United States Pharmacopeia), BAN (British Approved Name), DCF (Dénomination Commune Française), and JAN (Japanese Accepted Name). Its name is spironolactonum in Latin, Spironolacton in German, espironolactona in Spanish and Portuguese, and spironolattone in Italian (which is also its DCIT (Denominazione Comune Italiana)).[107][108][291][292] WP

Spironolactone is also known by its developmental code names SC-9420 and NSC-150339.[107][108][291] WP

Brand names

Spironolactone is marketed under various brand names throughout the world. The original brand name of spironolactone is Aldactone. Other brand names include Aldactone-A, Berlactone, CaroSpir, Espironolactona, Espironolactona Genfar, Novo-Spiroton, Prilactone (veterinary), Spiractin, Spiridon, Spirix, Spiroctan, Spiroderm (discontinued), Spirogamma, Spirohexal, Spirolon, Spirolone, Spiron, Spironolactone Actavis, Spironolactone Orion, Spironolactone Teva, Spirotone, Tempora (veterinary), Uractone, Uractonum, Verospiron, and Vivitar.[106][107][108] WP

Spironolactone is also formulated in combination with a variety of other medications, including with hydrochlorothiazide as Aldactazide, with hydroflumethiazide as Aldactide, Lasilacton, Lasilactone, and Spiromide, with altizide as Aldactacine and Aldactazine, with furosemide as Fruselac, with benazepril as Cardalis (veterinary), with metolazone as Metolactone, with bendroflumethiazide as Sali-Aldopur, and with torasemide as Dytor Plus, Torlactone, and Zator Plus.[108][293] WP

Availability

Spironolactone is marketed throughout the world.[107][108] WP

Chemistry

Formula

C24H32O4S PC

CAS number

52-01-7 PC

Molar mass (g/mol)

416.6 PC

IUPAC name (computed by PubChem)

S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate PC

SMILES

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C PC

InChIKey

LXMSZDCAJNLERA-ZHYRCANASA-N PC

PubChem CID

5833

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Australian Medicines Handbook
2. Other Spironolactone
3. Journal / agency Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England Journal of Medicine. September 1999. doi:10.1056/NEJM199909023411001 · PMID 10471456
4. Journal / agency Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, Chen W, Yang J, Li J. Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. Medicine. August 2018. doi:10.1097/MD.0000000000011942 · PMID 30170387 · PMC6392615
5. Journal / agency Friedman AJ. Spironolactone for Adult Female Acne. Cutis. October 2015. PMID 27141564
6. Other Maizes V. Integrative Women's Health. 2015
7. Journal / agency Sinnott SJ, Tomlinson LA, Root AA, Mathur R, Mansfield KE, Smeeth L, Douglas IJ. Comparative effectiveness of fourth-line antihypertensive agents in resistant hypertension: A systematic review and meta-analysis. European Journal of Preventive Cardiology. February 2017. doi:10.1177/2047487316675194 · PMID 27856806
8. Journal / agency Coleman E, Radix AE, Bouman WP, Brown GR, de Vries AL, Deutsch MB, Ettner R, Fraser L, Goodman M, Green J, Hancock AB, Johnson TW, Karasic DH, Knudson GA, Leibowitz SF, Meyer-Bahlburg HF, Monstrey SJ, Motmans J, Nahata L, Nieder TO, Reisner SL, Richards C, Schechter LS, Tangpricha V, Tishelman AC, Van Trotsenburg MA, Winter S, Ducheny K, Adams NJ, Adrián TM, Allen LR, Azul D, Bagga H, Başar K, Bathory DS, Belinky JJ, Berg DR, Berli JU, Bluebond-Langner RO, Bouman MB, Bowers ML, Brassard PJ, Byrne J, Capitán L, Cargill CJ, Carswell JM, Chang SC, Chelvakumar G, Corneil T, Dalke KB, De Cuypere G, de Vries E, Den Heijer M, Devor AH, Dhejne C, D'Marco A, Edmiston EK, Edwards-Leeper L, Ehrbar R, Ehrensaft D, Eisfeld J, Elaut E, Erickson-Schroth L, Feldman JL, Fisher AD, Garcia MM, Gijs L, Green SE, Hall BP, Hardy TL, Irwig MS, Jacobs LA, Janssen AC, Johnson K, Klink DT, Kreukels BP, Kuper LE, Kvach EJ, Malouf MA, Massey R, Mazur T, McLachlan C, Morrison SD, Mosser SW, Neira PM, Nygren U, Oates JM, Obedin-Maliver J, Pagkalos G, Patton J, Phanuphak N, Rachlin K, Reed T, Rider GN, Ristori J, Robbins-Cherry S, Roberts SA, Rodriguez-Wallberg KA, Rosenthal SM, Sabir K, Safer JD, Scheim AI, Seal LJ, Sehoole TJ, Spencer K, St Amand C, Steensma TD, Strang JF, Taylor GB, Tilleman K, T'Sjoen GG, Vala LN, Van Mello NM, Veale JF, Vencill JA, Vincent B, Wesp LM, West MA, Arcelus J. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health. 19 August 2022. doi:10.1080/26895269.2022.2100644 · PMID 36238954 · PMC9553112
9. Journal / agency Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism. November 2017. doi:10.1210/jc.2017-01658 · PMID 28945902
10. Other Deutsch M. Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People. 17 June 2016
11. Journal / agency Liszewski W, Boull C. Lack of evidence for feminization of males exposed to spironolactone in utero: A systematic review. Journal of the American Academy of Dermatology. April 2019. doi:10.1016/j.jaad.2018.10.023 · PMID 30352280
12. Journal / agency Landau E, Amar L. Primary aldosteronism and pregnancy. Annales d'Endocrinologie. June 2016. doi:10.1016/j.ando.2016.04.009 · PMID 27156905
13. Journal / agency Deng N, Zhong J, Deng Z, Chen M, Yan L, Li H, Han J, Tao E. Case report: A pregnant woman accidental treated with spironolactone in mid-gestation. Frontiers in Pharmacology. 25 July 2024. doi:10.3389/fphar.2024.1404251 · PMID 39119600 · PMC11306061
14. Journal / agency Burinkul S, Panyakhamlerd K, Suwan A, Tuntiviriyapun P, Wainipitapong S. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial. The Journal of Sexual Medicine. July 2021. doi:10.1016/j.jsxm.2021.05.003 · PMID 34274044
15. Journal / agency Sehgal I. Review of adult gender transition medications: mechanisms, efficacy measures, and pharmacogenomic considerations. Frontiers in Endocrinology. 2023. doi:10.3389/fendo.2023.1184024 · PMID 37476490 · PMC10355117
16. Other Deedwania PC. Drug & Device Selection in Heart Failure. 30 January 2014
17. Other Ottow E, Weinmann H. Nuclear Receptors As Drug Targets. 9 July 2008
18. Other Wermuth CG. The Practice of Medicinal Chemistry. 24 July 2008
19. Other Sittig M. Pharmaceutical Manufacturing Encyclopedia. 1988
20. Journal / agency World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. 2025. doi:10.2471/B09474
21. Other Top 300 of 2023
22. Other Spironolactone Drug Usage Statistics, United States, 2014 - 2023
23. Journal / agency Prior JC, Vigna YM, Watson D. Spironolactone with Physiological Female Steroids for Presurgical Therapy of Male-To-Female Transsexualism. Archives of Sexual Behavior. 1989. doi:10.1007/BF01579291 · PMID 2540730
24. Journal / agency Bayoumi E, Lam PH, Dooley DJ, Singh S, Faselis C, Morgan CJ, Patel S, Sheriff HM, Mohammed SF, Palant CE, Pitt B, Fonarow GC, Ahmed A. Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction. The American Journal of Medicine. January 2019. doi:10.1016/j.amjmed.2018.09.011 · PMID 30240686 · PMC6511886
25. Journal / agency Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, Lam CS, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Solomon SD, McMurray JJ. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. September 2024. doi:10.1016/S0140-6736(24)01733-1 · PMID 39232490
26. Journal / agency Pamporis K, Karakasis P, Sagris M, Zarifis I, Bougioukas KI, Pagkalidou E, Milaras N, Samaras A, Theofilis P, Fragakis N, Tousoulis D, Xanthos T, Giannakoulas G. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials. Current Problems in Cardiology. July 2024. doi:10.1016/j.cpcardiol.2024.102615 · PMID 38692445
27. Journal / agency Li S, Zhang X, Dong M, Gong S, Shang Z, Jia X, Chen W, Yang J, Li J. Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials. Medicine. August 2018. doi:10.1097/md.0000000000011942 · PMID 30170387 · PMC6392615
28. Journal / agency Ferreira JP, Cleland JG, Girerd N, Bozec E, Rossignol P, Pellicori P, Cosmi F, Mariottoni B, Solomon SD, Pitt B, Pfeffer MA, Shah AM, Petutschnigg J, Pieske B, Edelmann F, Zannad F. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. European Journal of Heart Failure. January 2023. doi:10.1002/ejhf.2726 · PMID 36303266 · PMC12611554
29. Journal / agency Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. The New England Journal of Medicine. April 2014. doi:10.1056/NEJMoa1313731 · PMID 24716680
30. Journal / agency Tsujimoto T, Kajio H. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension. Journal of the American Heart Association. December 2020. doi:10.1161/jaha.120.018827 · PMID 33222584 · PMC7763779
31. Journal / agency Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. November 2015. doi:10.1016/s0140-6736(15)00257-3 · PMID 26414968 · PMC4655321
32. Other Ronco C, Bellomo R, Kellum JA, Ricci Z. Critical Care Nephrology E-Book. 14 December 2017
33. Journal / agency Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney International. April 2000. doi:10.1046/j.1523-1755.2000.00983.x · PMID 10760075
34. Journal / agency Endou H, Hosoyamada M. Diuretics. 1995. doi:10.1007/978-3-642-79565-7_9
35. Journal / agency Santer M, Lawrence M, Renz S, Eminton Z, Stuart B, Sach TH, Pyne S, Ridd MJ, Francis N, Soulsby I, Thomas K, Permyakova N, Little P, Muller I, Nuttall J, Griffiths G, Thomas KS, Layton AM. Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ. May 2023. doi:10.1136/bmj-2022-074349 · PMID 37192767 · PMC10543374
36. Journal / agency Kow CS, Ramachandram DS, Hasan SS, Thiruchelvam K. Spironolactone for the Treatment of Moderate to Severe Acne in Adult Women: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. The Australasian Journal of Dermatology. May 2025. doi:10.1111/ajd.14428 · PMID 39912292
37. Journal / agency Hughes BR, Cunliffe WJ. Tolerance of spironolactone. The British Journal of Dermatology. May 1988. doi:10.1111/j.1365-2133.1988.tb02571.x · PMID 2969259
38. Other Preedy VR. Handbook of Hair in Health and Disease. 1 January 2012
39. Journal / agency Loy R, Seibel MM. Evaluation and therapy of polycystic ovarian syndrome. Endocrinology and Metabolism Clinics of North America. December 1988. doi:10.1016/S0889-8529(18)30410-9 · PMID 3143568
40. Journal / agency Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, Okumura T, Kida K, Mizuno A, Oishi S, Inuzuka Y, Akiyama E, Matsukawa R, Kato K, Suzuki S, Naruke T, Yoshioka K, Miyoshi T, Baba Y, Yamamoto M, Murai K, Mizutani K, Yoshida K, Kitai T. Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. Journal of the American College of Cardiology. June 2017. doi:10.1016/j.jacc.2017.04.042 · PMID 28641794
41. Journal / agency Burnett H, Earley A, Voors AA, Senni M, McMurray JJ, Deschaseaux C, Cope S. Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. Circulation: Heart Failure. January 2017. doi:10.1161/CIRCHEARTFAILURE.116.003529 · PMID 28087688 · PMC5265698
42. Journal / agency Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. The New England Journal of Medicine. January 2011. doi:10.1056/NEJMoa1009492 · PMID 21073363
43. Journal / agency Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. October 2013. doi:10.1016/j.jacc.2013.05.019 · PMID 23747642
44. Journal / agency Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E. Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Annals of Translational Medicine. December 2018. doi:10.21037/atm.2018.11.16 · PMID 30603649 · PMC6312809
45. Journal / agency Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N, Mukherjee D. Eplerenone is not superior to older and less expensive aldosterone antagonists. The American Journal of Medicine. August 2012. doi:10.1016/j.amjmed.2011.12.018 · PMID 22840667
46. Journal / agency Elshahat A, Mansour A, Ellabban M, Diaa A, Hassan A, Fawzy A, Saad OA, Abouelmagd M, Eid M, Elaraby A, Elkasaby MH, Abdelaziz A. Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis. BMC Cardiovascular Disorders. September 2024. doi:10.1186/s12872-024-04103-7 · PMID 39271992 · PMC11395778
47. Journal / agency Frankenstein L, Seide S, Täger T, Jensen K, Fröhlich H, Clark AL, Seiz M, Katus HA, Nee P, Uhlmann L, Naci H, Atar D. Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. Heart Failure Reviews. March 2020. doi:10.1007/s10741-019-09832-y · PMID 31364027
48. Journal / agency Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for hypertension. The Cochrane Database of Systematic Reviews. August 2010. doi:10.1002/14651858.CD008169.pub2 · PMID 20687095
49. Journal / agency Stavropoulos K, Papadopoulos C, Koutsampasopoulos K, Lales G, Mitas C, Doumas M. Mineralocorticoid Receptor Antagonists in Primary Aldosteronism. Current Pharmaceutical Design. 2018. doi:10.2174/1381612825666190311130138 · PMID 30854950
50. Journal / agency Forestiero V, Sconfienza E, Mulatero P, Monticone S. Primary aldosteronism in pregnancy. Reviews in Endocrine & Metabolic Disorders. May 2022. doi:10.1007/s11154-022-09729-6 · PMID 35536535 · PMC9884655
51. Journal / agency Riester A, Reincke M. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. European Journal of Endocrinology. January 2015. doi:10.1530/EJE-14-0444 · PMID 25163723
52. Journal / agency Araujo-Castro M. Treatment of primary hyperaldosteronism. Medicina Clinica. October 2020. doi:10.1016/j.medcli.2020.04.029 · PMID 32586668
53. Journal / agency Zouboulis CC, Degitz K. Androgen action on human skin -- from basic research to clinical significance. Experimental Dermatology. 2004. doi:10.1111/j.1600-0625.2004.00255.x · PMID 15507105
54. Journal / agency Endly DC, Miller RA. Oily Skin: A review of Treatment Options. The Journal of Clinical and Aesthetic Dermatology. August 2017. PMID 28979664 · PMC5605215
55. Other Shalita AR, Del Rosso JQ, Webster G. Acne Vulgaris. 21 March 2011
56. Other Zouboulis CC, Katsambas AD, Kligman AM. Pathogenesis and Treatment of Acne and Rosacea. 28 July 2014
57. Journal / agency Marks LS. 5alpha-reductase: history and clinical importance. Reviews in Urology. 2004. PMID 16985920 · PMC1472916
58. Other Sloane E. Biology of Women. 2002
59. Other Hanno PM, Guzzo TJ, Malkowicz SB, Wein AJ. Penn Clinical Manual of Urology E-Book: Expert Consult - Online. 26 January 2014
60. Other Harper C. Intersex. 1 August 2007
61. Other Blume-Peytavi U, Whiting DA, Trüeb RM. Hair Growth and Disorders. 26 June 2008
62. Journal / agency Diamanti-Kandarakis E, Tolis G, Duleba AJ. Androgens and therapeutic aspects of antiandrogens in women. Journal of the Society for Gynecologic Investigation. 1995. doi:10.1177/107155769500200401 · PMID 9420861
63. Journal / agency Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first line therapy? facts and controversies. Clinics in Dermatology. 2010. doi:10.1016/j.clindermatol.2009.03.006 · PMID 20082945
64. Journal / agency Kim GK, Del Rosso JQ. Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. The Journal of Clinical and Aesthetic Dermatology. March 2012. PMID 22468178 · PMC3315877
65. Journal / agency Layton AM, Eady EA, Whitehouse H, Del Rosso JQ, Fedorowicz Z, van Zuuren EJ. Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review. American Journal of Clinical Dermatology. April 2017. doi:10.1007/s40257-016-0245-x · PMID 28155090 · PMC5360829
66. Journal / agency Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology. May 2016. doi:10.1016/j.jaad.2015.12.037 · PMID 26897386
67. Journal / agency Shaw JC. Antiandrogen and hormonal treatment of acne. Dermatologic Clinics. October 1996. doi:10.1016/S0733-8635(05)70405-8 · PMID 9238337
68. Journal / agency Somani N, Turvy D. Hirsutism: an evidence-based treatment update. American Journal of Clinical Dermatology. July 2014. doi:10.1007/s40257-014-0078-4 · PMID 24889738
69. Journal / agency Rathnayake D, Sinclair R. Use of spironolactone in dermatology. Skinmed. 2010. PMID 21413648
70. Journal / agency Harfmann KL, Bechtel MA. Hair loss in women. Clinical Obstetrics and Gynecology. March 2015. doi:10.1097/GRF.0000000000000081 · PMID 25517757
71. Journal / agency Iswaran TJ, Imai M, Betton GR, Siddall RA. An overview of animal toxicology studies with bicalutamide (ICI 176,334). The Journal of Toxicological Sciences. May 1997. doi:10.2131/jts.22.2_75 · PMID 9198005
72. Other Smith RE. Medicinal Chemistry – Fusion of Traditional and Western Medicine. 4 April 2013
73. Other Ostrzenski A. Gynecology: Integrating Conventional, Complementary, and Natural Alternative Therapy. 2002
74. Journal / agency Schmidt JB. Other antiandrogens. Dermatology. 1998. doi:10.1159/000017850 · PMID 9557251
75. Journal / agency Prior JC, Vigna YM, Watson D. Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Archives of Sexual Behavior. February 1989. doi:10.1007/bf01579291 · PMID 2540730
76. Journal / agency Cunliffe WJ, Bottomley WW. Antiandrogens and acne. A topical approach?. Archives of Dermatology. September 1992. doi:10.1001/archderm.1992.01680190117017 · PMID 1387779
77. Journal / agency Vincenzi C, Trevisi P, Farina P, Stinchi C, Tosti A. Facial contact dermatitis due to spironolactone in an anti-acne cream. Contact Dermatitis. November 1993. doi:10.1111/j.1600-0536.1993.tb03569.x · PMID 8112074
78. Journal / agency Benvenga S. Diagnosis and Management of Polycystic Ovary Syndrome. 2009. doi:10.1007/978-0-387-09718-3_19
79. Journal / agency van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). The Cochrane Database of Systematic Reviews. April 2015. doi:10.1002/14651858.CD010334.pub2 · PMID 25918921 · PMC6481758
80. Journal / agency Barrionuevo P, Nabhan M, Altayar O, Wang Z, Erwin PJ, Asi N, Martin KA, Murad MH. Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis. The Journal of Clinical Endocrinology and Metabolism. April 2018. doi:10.1210/jc.2017-02052 · PMID 29522176
81. Journal / agency Erem C. Update on idiopathic hirsutism: diagnosis and treatment. Acta Clinica Belgica. 2013. doi:10.2143/ACB.3267 · PMID 24455796
82. Journal / agency Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, Motta C, De Leo V, Petraglia F, Lenzi A. Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial. The Journal of Clinical Endocrinology and Metabolism. March 2018. doi:10.1210/jc.2017-01186 · PMID 29211888
83. Journal / agency Kamangar F, Shinkai K. Acne in the adult female patient: a practical approach. International Journal of Dermatology. October 2012. doi:10.1111/j.1365-4632.2012.05519.x · PMID 22994662
84. Journal / agency Diamanti-Kandarakis E. Current aspects of antiandrogen therapy in women. Current Pharmaceutical Design. September 1999. doi:10.2174/1381612805666230111201150 · PMID 10495361
85. Other Shelley WB, Shelley ED. Advanced Dermatologic Therapy II. 2001
86. Other Balen A, Franks S, Homburg R, Kehoe S. Current Management of Polycystic Ovary Syndrome. October 2010
87. Journal / agency Giorgetti R, di Muzio M, Giorgetti A, Girolami D, Borgia L, Tagliabracci A. Flutamide-induced hepatotoxicity: ethical and scientific issues. European Review for Medical and Pharmacological Sciences. March 2017. PMID 28379593
88. Journal / agency Trivedi MK, Shinkai K, Murase JE. A Review of hormone-based therapies to treat adult acne vulgaris in women. International Journal of Women's Dermatology. March 2017. doi:10.1016/j.ijwd.2017.02.018 · PMID 28492054 · PMC5419026
89. Journal / agency Yasa C, Dural Ö, Bastu E, Uğurlucan FG. Hirsutism, Acne, and Hair Loss: Management of Hyperandrogenic Cutaneous Manifestations of Polycystic Ovary Syndrome. Gynecology Obstetrics & Reproductive Medicine. 2016. doi:10.21613/GORM.2016.613
90. Journal / agency Barros B, Thiboutot D. Hormonal therapies for acne. Clinics in Dermatology. 2017. doi:10.1016/j.clindermatol.2016.10.009 · PMID 28274354
91. Journal / agency Hassoun LA, Chahal DS, Sivamani RK, Larsen LN. The use of hormonal agents in the treatment of acne. Seminars in Cutaneous Medicine and Surgery. June 2016. doi:10.12788/j.sder.2016.027 · PMID 27416311
92. Journal / agency Azarchi S, Bienenfeld A, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Androgens in women: Hormone-modulating therapies for skin disease. Journal of the American Academy of Dermatology. June 2019. doi:10.1016/j.jaad.2018.08.061 · PMID 30312645
93. Journal / agency van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. The Cochrane Database of Systematic Reviews. May 2016. doi:10.1002/14651858.CD007628.pub4 · PMID 27225981 · PMC6457957
94. Journal / agency Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. The Cochrane Database of Systematic Reviews. April 2009. doi:10.1002/14651858.CD000194.pub2 · PMID 19370553
95. Journal / agency Hammerstein J. Hair and Hair Diseases. 1990. doi:10.1007/978-3-642-74612-3_35
96. Journal / agency Glintborg D, T'Sjoen G, Ravn P, Andersen MS. MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender people. European Journal of Endocrinology. June 2021. doi:10.1530/EJE-21-0059 · PMID 34081614
97. Journal / agency Angus LM, Nolan BJ, Zajac JD, Cheung AS. A systematic review of antiandrogens and feminization in transgender women. Clinical Endocrinology. May 2021. doi:10.1111/cen.14329 · PMID 32926454
98. Journal / agency Haupt C, Henke M, Kutschmar A, Hauser B, Baldinger S, Saenz SR, Schreiber G. Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women. The Cochrane Database of Systematic Reviews. November 2020. doi:10.1002/14651858.CD013138.pub2 · PMID 33251587 · PMC8078580
99. Journal / agency Misakian AL, Ariel D, Sullivan EA, Singh G, Loeb D, Strickland T, Iwamoto SJ, Rothman MS, Botzheim B, Liang JW, Kelley C, Hamnvik OR. Injectable Estradiol Monotherapy Effectively Suppresses Testosterone in Gender-Affirming Hormone Therapy. Endocrine Practice. November 2025. doi:10.1016/j.eprac.2025.07.002 · PMID 40639470
100. Journal / agency Angus LM, Leemaqz SY, Kasielska-Trojan AK, Mikołajczyk M, Doery JC, Zajac JD, Cheung AS. Effect of Spironolactone and Cyproterone Acetate on Breast Growth in Transgender People: A Randomized Clinical Trial. The Journal of Clinical Endocrinology and Metabolism. May 2025. doi:10.1210/clinem/dgae650 · PMID 39288020 · PMC12086416
101. Other Muller NF, Dessing RP. European Drug Index: European Drug Registrations. 19 June 1998
102. Other Lee M, Desai A. Gibaldi's Drug Delivery Systems in Pharmaceutical Care. 2007
103. Other Niazi SK. Handbook of Pharmaceutical Manufacturing Formulations, Second Edition: Volume One, Compressed Solid Products. 19 April 2016
104. Other Wakelin SH, Maibach HI, Archer CB. Systemic Drug Treatment in Dermatology: A Handbook. 1 June 2002
105. Journal / agency Drugs@FDA: FDA Approved Drug Products
106. Other Farid NR, Diamanti-Kandarakis E. Diagnosis and Management of Polycystic Ovary Syndrome. 27 February 2009
107. Other Index Nominum 2000: International Drug Directory. January 2000
108. Other Spironolactone
109. Journal / agency Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Failure Reviews. January 2005. doi:10.1007/s10741-005-2345-1 · PMID 15947888
110. Journal / agency Kolkhof P, Bärfacker L. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. The Journal of Endocrinology. July 2017. doi:10.1530/JOE-16-0600 · PMID 28634268 · PMC5488394
111. Journal / agency Aldactone- spironolactone tablet, film coated. 29 November 2018
112. Other Goldsmith D, Covic A, Spaak J. Cardio-Renal Clinical Challenges. 12 November 2014
113. Journal / agency Loriaux DL. Spironolactone and endocrine dysfunction. Annals of Internal Medicine. November 1976. doi:10.7326/0003-4819-85-5-630 · PMID 984618
114. Other Seldin DW, Giebisch GH. Diuretic Agents: Clinical Physiology and Pharmacology. 23 September 1997
115. Other Aronson JK. Meyler's Side Effects of Cardiovascular Drugs. 2 March 2009
116. Other Carrell DT, Peterson CM. Reproductive Endocrinology and Infertility: Integrating Modern Clinical and Laboratory Practice. 23 March 2010
117. Other Pescovitz OH, Eugster EA. Pediatric Endocrinology: Mechanisms, Manifestations, and Management. 2004
118. Journal / agency Secora AM, Shin JI, Qiao Y, Alexander GC, Chang AR, Inker LA, Coresh J, Grams ME. Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure. Mayo Clinic Proceedings. November 2020. doi:10.1016/j.mayocp.2020.03.035 · PMID 33153631 · PMC8005315
119. Journal / agency Spironolactone. 2019
120. Journal / agency Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M. Spironolactone and risk of upper gastrointestinal events: population based case-control study. BMJ. August 2006. doi:10.1136/bmj.38883.479549.2F · PMID 16840442 · PMC1539051
121. Journal / agency Gulmez SE, Lassen AT, Aalykke C, Dall M, Andries A, Andersen BS, Hansen JM, Andersen M, Hallas J. Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study. British Journal of Clinical Pharmacology. August 2008. doi:10.1111/j.1365-2125.2008.03205.x · PMID 18507655 · PMC2492928
122. Journal / agency Wandelt-Freerksen E. Aldactone in the treatment of sarcoidosis of the lungs (author's transl). Zeitschrift für Erkrankungen der Atmungsorgane. July 1977. PMID 607621
123. Journal / agency Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, Speziale G, Gaudio C. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. International Journal of Cardiology. December 2015. doi:10.1016/j.ijcard.2015.05.127 · PMID 26404748
124. Journal / agency Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. The New England Journal of Medicine. August 2004. doi:10.1056/NEJMoa040135 · PMID 15295047
125. Journal / agency Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O'Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Piña IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. European Heart Journal. November 2012. doi:10.1093/eurheartj/ehs257 · PMID 22942339
126. Journal / agency Wei L, Struthers AD, Fahey T, Watson AD, Macdonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ. May 2010. doi:10.1136/bmj.c1768 · PMID 20483947
127. Journal / agency Antoniou T, Gomes T, Mamdani MM, Yao Z, Hellings C, Garg AX, Weir MA, Juurlink DN. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. BMJ. September 2011. doi:10.1136/bmj.d5228 · PMID 21911446 · PMC3171211
128. Journal / agency Antoniou T, Hollands S, Macdonald EM, Gomes T, Mamdani MM, Juurlink DN. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ. March 2015. doi:10.1503/cmaj.140816 · PMID 25646289 · PMC4347789
129. Journal / agency Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatology. September 2015. doi:10.1001/jamadermatol.2015.34 · PMID 25796182
130. Journal / agency Millington K, Liu E, Chan YM. The Utility of Potassium Monitoring in Gender-Diverse Adolescents Taking Spironolactone. Journal of the Endocrine Society. May 2019. doi:10.1210/js.2019-00030 · PMID 31065620 · PMC6497918
131. Journal / agency Hayes H, Russell R, Haugen A, Nagavally S, Sarvaideo J. The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone. Journal of the Endocrine Society. October 2022. doi:10.1210/jendso/bvac133 · PMID 36267595 · PMC9562816
132. Other Becker KL. Principles and Practice of Endocrinology and Metabolism. 2001
133. Other Tsioufis C, Schmieder R, Mancia G. Interventional Therapies for Secondary and Essential Hypertension. 15 August 2016
134. Journal / agency Conn JJ, Jacobs HS. Managing hirsutism in gynaecological practice. British Journal of Obstetrics and Gynaecology. July 1998. doi:10.1111/j.1471-0528.1998.tb10197.x · PMID 9692407
135. Other Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions. 1 December 2014
136. Other McInnes GT. Clinical Pharmacology and Therapeutics of Hypertension. 2008
137. Journal / agency Ménard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Molecular and Cellular Endocrinology. March 2004. doi:10.1016/j.mce.2003.10.008 · PMID 15134800
138. Journal / agency Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy. 1993. doi:10.1002/j.1875-9114.1993.tb02688.x · PMID 8094898
139. Other Wilcox CS. Therapy in Nephrology and Hypertension E-Book: A Companion to Brenner & Rector's The Kidney. 22 August 2008
140. Journal / agency Eckman A, Dobs A. Drug-induced gynecomastia. Expert Opinion on Drug Safety. November 2008. doi:10.1517/14740330802442382 · PMID 18983216
141. Journal / agency Mathur R, Braunstein GD. Gynecomastia: pathomechanisms and treatment strategies. Hormone Research. 1997. doi:10.1159/000185497 · PMID 11546925
142. Journal / agency Christy NA, Franks AS, Cross LB. Spironolactone for hirsutism in polycystic ovary syndrome. The Annals of Pharmacotherapy. September 2005. doi:10.1345/aph.1G025 · PMID 16076921
143. Journal / agency Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clinical Endocrinology. May 2000. doi:10.1046/j.1365-2265.2000.00982.x · PMID 10792338
144. Journal / agency Rabe T, Grunwald K, Feldmann K, Runnebaum B. Treatment of hyperandrogenism in women. Gynecological Endocrinology. 2009. doi:10.3109/09513599609045658
145. Journal / agency McMullen GR, Van Herle AJ. Hirsutism and the effectiveness of spironolactone in its management. Journal of Endocrinological Investigation. December 1993. doi:10.1007/BF03348960 · PMID 8144871
146. Journal / agency Nakajima ST, Brumsted JR, Riddick DH, Gibson M. Absence of progestational activity of oral spironolactone. Fertility and Sterility. July 1989. doi:10.1016/s0015-0282(16)60807-5 · PMID 2744183
147. Journal / agency Olsson HL, Olsson ML. The Menstrual Cycle and Risk of Breast Cancer: A Review. Frontiers in Oncology. 2020. doi:10.3389/fonc.2020.00021 · PMID 32038990 · PMC6993118
148. Other Jemec G, Revuz J, Leyden JJ. Hidradenitis Suppurativa. 24 November 2006
149. Journal / agency ter Heegde F, De Rijk RH, Vinkers CH. The brain mineralocorticoid receptor and stress resilience. Psychoneuroendocrinology. February 2015. doi:10.1016/j.psyneuen.2014.10.022 · PMID 25459896
150. Journal / agency Schultebraucks K. The Role of the Mineralocorticoid Receptor for Cognitive Function, Mood and Social Cognition. 2016. doi:10.17169/refubium-6940
151. Journal / agency Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. Journal of Psychiatric Research. 1999. doi:10.1016/S0022-3956(98)90056-5 · PMID 10367986
152. Journal / agency Basson R, Prior JC. Current Concepts in Transgender Identity. 1998. doi:10.4324/9780203775134
153. Journal / agency Baldani DP, Skrgatic L, Ougouag R, Kasum M. The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment. Gynecological Endocrinology. February 2018. doi:10.1080/09513590.2017.1381681 · PMID 28944709
154. Journal / agency Nakhjavani M, Hamidi S, Esteghamati A, Abbasi M, Nosratian-Jahromi S, Pasalar P. Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. British Journal of Clinical Pharmacology. October 2009. doi:10.1111/j.1365-2125.2009.03483.x · PMID 19843067 · PMC2780289
155. Journal / agency Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. June 2019. doi:10.1161/CIR.0000000000000625 · PMID 30586774 · PMC7403606
156. Journal / agency Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions. American Heart Journal. December 1987. doi:10.1016/0002-8703(87)90552-7 · PMID 3318361
157. Journal / agency Cignarella A, Mioni R, Sabbadin C, Dassie F, Parolin M, Vettor R, Barbot M, Scaroni C. Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS. International Journal of Molecular Sciences. December 2020. doi:10.3390/ijms21249554 · PMID 33334002 · PMC7765466
158. Journal / agency Lopes RJ, Lourenço AP, Mascarenhas J, Azevedo A, Bettencourt P. Safety of spironolactone use in ambulatory heart failure patients. Clinical Cardiology. November 2008. doi:10.1002/clc.20284 · PMID 19006114 · PMC6652974
159. Journal / agency Thai KE, Sinclair RD. Spironolactone-induced hepatitis. The Australasian Journal of Dermatology. August 2001. doi:10.1046/j.1440-0960.2001.00510.x · PMID 11488711
160. Journal / agency Aldactazide (spironolactone/hydrochlorothiazide) Tablets
161. Other online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7699#f_adverse-reactions
162. Journal / agency Aiba M, Suzuki H, Kageyama K, Murai M, Tazaki H, Abe O, Saruta T. Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa. The American Journal of Pathology. June 1981. PMID 7195152 · PMC1903848
163. Other Ainsworth SB. Neonatal Formulary: Drug Use in Pregnancy and the First Year of Life. 10 November 2014
164. Other Little B. Drugs and Pregnancy: A Handbook. 29 September 2006
165. Other Rubin PC, Ramsey M. Prescribing in Pregnancy. 30 April 2008
166. Other Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 2011
167. Other Gleicher N, Elkayam U, Gleicher N. Cardiac Problems in Pregnancy: Diagnosis and Management of Maternal and Fetal Heart Disease. 23 June 1998
168. Other Schaefer C. Drugs During Pregnancy and Lactation: Handbook of Prescription Drugs and Comparative Risk Assessment. 2001
169. Other Upfal J. Australian Drug Guide. 2006
170. Journal / agency Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Molecular and Cellular Endocrinology. March 2004. doi:10.1016/j.mce.2003.10.005 · PMID 15134797
171. Other Advisory Statement
172. Journal / agency Juvet T, Gourineni VC, Ravi S, Zarich SW. Life-threatening hyperkalemia: a potentially lethal drug combination. Connecticut Medicine. September 2013. PMID 24156179
173. Other Parkinson A. Biotransformation of Xenobiotics. 2001
174. Other Davis MP. Opioids in Cancer Pain. 28 May 2009
175. Journal / agency Shaw JC. Spironolactone in dermatologic therapy. Journal of the American Academy of Dermatology. February 1991. doi:10.1016/0190-9622(91)70034-Y · PMID 1826112
176. Other Wolverton SE. Comprehensive Dermatologic Drug Therapy. 8 March 2007
177. Journal / agency Leinung MC, Feustel PJ, Joseph J. Hormonal Treatment of Transgender Women with Oral Estradiol. Transgender Health. 2018. doi:10.1089/trgh.2017.0035 · PMID 29756046 · PMC5944393
178. Journal / agency Jhajra S, Ramesh Varkhede N, Suresh Ahire D, Vidyasagar Naik B, Prasad B, Paliwal J, Singh S. Encyclopedia of Drug Metabolism and Interactions. 2012. doi:10.1002/9780470921920.edm028
179. Journal / agency Armanini D, Andrisani A, Bordin L, Sabbadin C. Spironolactone in the treatment of polycystic ovary syndrome. Expert Opinion on Pharmacotherapy. September 2016. doi:10.1080/14656566.2016.1215430 · PMID 27450358
180. Journal / agency Armanini D, Castello R, Scaroni C, Bonanni G, Faccini G, Pellati D, Bertoldo A, Fiore C, Moghetti P. Treatment of polycystic ovary syndrome with spironolactone plus licorice. European Journal of Obstetrics, Gynecology, and Reproductive Biology. March 2007. doi:10.1016/j.ejogrb.2006.10.013 · PMID 17113210
181. Journal / agency Salassa RM, Mattox VR, Rosevear JW. Inhibition of the "mineralocorticoid" activity of licorice by spironolactone. The Journal of Clinical Endocrinology and Metabolism. November 1962. doi:10.1210/jcem-22-11-1156 · PMID 13991036
182. Journal / agency Omar HR, Komarova I, El-Ghonemi M, Fathy A, Rashad R, Abdelmalak HD, Yerramadha MR, Ali Y, Helal E, Camporesi EM. Licorice abuse: time to send a warning message. Therapeutic Advances in Endocrinology and Metabolism. August 2012. doi:10.1177/2042018812454322 · PMID 23185686 · PMC3498851
183. Journal / agency Lin SH, Yang SS, Chau T, Halperin ML. An unusual cause of hypokalemic paralysis: chronic licorice ingestion. The American Journal of the Medical Sciences. March 2003. doi:10.1097/00000441-200303000-00008 · PMID 12640291
184. Journal / agency Parthasarathy HK, MacDonald TM. Mineralocorticoid receptor antagonists. Current Hypertension Reports. March 2007. doi:10.1007/s11906-007-0009-3 · PMID 17362671
185. Other Holsboer, F. The Rationale for Corticotropin-Releasing Hormone Receptor (CRH-R) Antagonists to Treat Depression and Anxiety. J. Psychiatr. Res. 33, 181–214 (1999)
186. Journal / agency Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K, Kellner M. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. Journal of Psychiatric Research. April 2010. doi:10.1016/j.jpsychires.2009.10.006 · PMID 19909979
187. Journal / agency Mostalac-Preciado CR, de Gortari P, López-Rubalcava C. Antidepressant-like effects of mineralocorticoid but not glucocorticoid antagonists in the lateral septum: interactions with the serotonergic system. Behavioural Brain Research. September 2011. doi:10.1016/j.bbr.2011.04.008 · PMID 21515309
188. Other Feldman AM. Heart Failure: Pharmacologic Management. 15 April 2008
189. Other Walar K. Pharmacology. 15 June 2015
190. Journal / agency Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert Opinion on Pharmacotherapy. April 2014. doi:10.1517/14656566.2014.879117 · PMID 24456327
191. Journal / agency Doggrell SA, Brown L. The spironolactone renaissance. Expert Opinion on Investigational Drugs. May 2001. doi:10.1517/13543784.10.5.943 · PMID 11322868
192. Other Strauss III JF, Barbieri RL. Yen and Jaffe's Reproductive Endocrinology. 13 September 2013
193. Journal / agency Tremblay RR. Treatment of hirsutism with spironolactone. Clinics in Endocrinology and Metabolism. May 1986. doi:10.1016/S0300-595X(86)80030-5 · PMID 2941190
194. Other Haff GG, Triplett NT. Essentials of Strength Training and Conditioning 4th Edition. 23 September 2015
195. Other Wu JJ. Comprehensive Dermatologic Drug Therapy E-Book. 18 October 2012
196. Other Coelingh Benni HJ, Vemer HM. Chronic Hyperandrogenic Anovulation. 15 December 1990
197. Journal / agency Shaw JC. Antiandrogen therapy in dermatology. International Journal of Dermatology. November 1996. doi:10.1111/j.1365-4362.1996.tb02970.x · PMID 8915726
198. Journal / agency Colby HD. Chemical suppression of steroidogenesis. Environmental Health Perspectives. April 1981. doi:10.1289/ehp.8138119 · PMID 6786868 · PMC1568425
199. Journal / agency Rocca ML, Venturella R, Mocciaro R, Di Cello A, Sacchinelli A, Russo V, Trapasso S, Zullo F, Morelli M. Polycystic ovary syndrome: chemical pharmacotherapy. Expert Opinion on Pharmacotherapy. June 2015. doi:10.1517/14656566.2015.1047344 · PMID 26001184
200. Journal / agency Ye P, Yamashita T, Pollock DM, Sasano H, Rainey WE. Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis. Hormone and Metabolic Research = Hormon- und Stoffwechselforschung = Hormones et Metabolisme. January 2009. doi:10.1055/s-0028-1087188 · PMID 18819053 · PMC4277847
201. Other Watts S, Faingold C, Dunaway G, Crespo L. Brody's Human Pharmacology - E-Book. 1 April 2009
202. Journal / agency Satoh T, Itoh S, Seki T, Itoh S, Nomura N, Yoshizawa I. On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production. The Journal of Steroid Biochemistry and Molecular Biology. October 2002. doi:10.1016/S0960-0760(02)00154-1 · PMID 12477487
203. Journal / agency Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH. Pathophysiology of spironolactone-induced gynecomastia. Annals of Internal Medicine. October 1977. doi:10.7326/0003-4819-87-4-398 · PMID 907238
204. Journal / agency Poirier D. Inhibitors of 17 beta-hydroxysteroid dehydrogenases. Current Medicinal Chemistry. March 2003. doi:10.2174/0929867033368222 · PMID 12570693
205. Journal / agency Poirier D. Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases. Anti-Cancer Agents in Medicinal Chemistry. July 2009. doi:10.2174/187152009788680000 · PMID 19601747
206. Journal / agency Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M. Spironolactone use and the risk of breast and gynecologic cancers. Cancer Epidemiology. December 2013. doi:10.1016/j.canep.2013.10.004 · PMID 24189467
207. Journal / agency Soubhye J, Alard IC, van Antwerpen P, Dufrasne F. Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis. Future Medicinal Chemistry. 2015. doi:10.4155/fmc.15.74 · PMID 26230882
208. Other Adams KF. Pharmacologic Approaches to Heart Failure, An Issue of Heart Failure Clinics, E-Book. 28 October 2014
209. Journal / agency Berardelli R, Karamouzis I, D'Angelo V, Zichi C, Fussotto B, Giordano R, Ghigo E, Arvat E. Role of mineralocorticoid receptors on the hypothalamus-pituitary-adrenal axis in humans. Endocrine. February 2013. doi:10.1007/s12020-012-9750-8 · PMID 22836869
210. Journal / agency Otte C, Moritz S, Yassouridis A, Koop M, Madrischewski AM, Wiedemann K, Kellner M. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. Neuropsychopharmacology. January 2007. doi:10.1038/sj.npp.1301217 · PMID 17035932
211. Journal / agency Hinkelmann K, Hellmann-Regen J, Wingenfeld K, Kuehl LK, Mews M, Fleischer J, Heuser I, Otte C. Mineralocorticoid receptor function in depressed patients and healthy individuals. Progress in Neuro-Psychopharmacology & Biological Psychiatry. November 2016. doi:10.1016/j.pnpbp.2016.08.003 · PMID 27519144
212. Other Falcone T, Hurd WW. Clinical Reproductive Medicine and Surgery. 1 January 2007
213. Journal / agency Abshagen U, Spörl S, L'age M. Non-interaction of spironolactone medication and cortisol metabolism in man. Klinische Wochenschrift. February 1978. doi:10.1007/BF01478568 · PMID 628197
214. Journal / agency Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure. American Heart Journal. November 2010. doi:10.1016/j.ahj.2010.04.024 · PMID 21095280
215. Other Kuntz E, Kuntz HD. Hepatology: Textbook and Atlas. 11 March 2009
216. Other Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams Textbook of Endocrinology E-Book. 12 May 2011
217. Journal / agency Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocrine Reviews. October 2002. doi:10.1210/er.2001-0038 · PMID 12372848
218. Journal / agency Sabbadin C, Andrisani A, Zermiani M, Donà G, Bordin L, Ragazzi E, Boscaro M, Ambrosini G, Armanini D. Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. Journal of Endocrinological Investigation. September 2016. doi:10.1007/s40618-016-0466-0 · PMID 27072668
219. Journal / agency Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. The Journal of Clinical Investigation. September 1998. doi:10.1172/JCI3703 · PMID 9727070 · PMC508967
220. Journal / agency Karim A. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metabolism Reviews. 1978. doi:10.3109/03602537808993782 · PMID 363379
221. Journal / agency Beermann B. Aspects on pharmacokinetics of some diuretics. Acta Pharmacologica et Toxicologica. 1984. doi:10.1111/j.1600-0773.1984.tb03626.x · PMID 6369882
222. Journal / agency Overdiek HW, Merkus FW. The metabolism and biopharmaceutics of spironolactone in man. Reviews on Drug Metabolism and Drug Interactions. 1987. doi:10.1515/DMDI.1987.5.4.273 · PMID 3333882
223. Journal / agency Brater DC. Update in diuretic therapy: clinical pharmacology. Seminars in Nephrology. November 2011. doi:10.1016/j.semnephrol.2011.09.003 · PMID 22099505
224. Journal / agency Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Molecular and Cellular Endocrinology. March 2012. doi:10.1016/j.mce.2011.06.025 · PMID 21771637
225. Journal / agency Yang J, Young MJ. Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences. Current Opinion in Pharmacology. April 2016. doi:10.1016/j.coph.2016.02.005 · PMID 26939027
226. Journal / agency Kolkhof P, Jaisser F, Kim SY, Filippatos G, Nowack C, Pitt B. Heart Failure. 2017. doi:10.1007/164_2016_76 · PMID 27830348
227. Journal / agency Maron BA, Leopold JA. Mineralocorticoid receptor antagonists and endothelial function. Current Opinion in Investigational Drugs. September 2008. PMID 18729003 · PMC2967484
228. Journal / agency Carone L, Oxberry SG, Twycross R, Charlesworth S, Mihalyo M, Wilcock A. Spironolactone. Journal of Pain and Symptom Management. February 2017. doi:10.1016/j.jpainsymman.2016.12.320 · PMID 28024992
229. Journal / agency Deinum J, Riksen NP, Lenders JW. Pharmacological treatment of aldosterone excess. Pharmacology & Therapeutics. October 2015. doi:10.1016/j.pharmthera.2015.07.006 · PMID 26213109
230. Journal / agency Overdiek HW, Merkus FW. Influence of food on the bioavailability of spironolactone. Clinical Pharmacology and Therapeutics. November 1986. doi:10.1038/clpt.1986.219 · PMID 3769384
231. Journal / agency Melander A, Danielson K, Scherstén B, Thulin T, Wåhlin E. Enhancement by food of canrenone bioavailability from spironolactone. Clinical Pharmacology and Therapeutics. July 1977. doi:10.1002/cpt1977221100 · PMID 872489
232. Journal / agency Saini-Chohan HK, Hatch GM. Biological actions and metabolism of currently used pharmacological agents for the treatment of congestive heart failure. Current Drug Metabolism. March 2009. doi:10.2174/138920009787846314 · PMID 19442083
233. Journal / agency Al-Hadiya BM, Belal F, Asiri YA, Gubara OA. Spironolactone. Analytical Profiles of Drug Substances and Excipients. 2002. doi:10.1016/S1075-6280(02)29009-6
234. Other International Agency for Research on Cancer; World Health Organization. Some Thyrotropic Agents. 2001
235. Other Aldosterone. 23 January 2019
236. Journal / agency Rey FO, Valterio C, Locatelli L, Ramelet AA, Felber JP. Lack of endocrine systemic side effects after topical application of spironolactone in man. Journal of Endocrinological Investigation. April 1988. doi:10.1007/BF03350151 · PMID 3411088
237. Journal / agency Takamura N, Maruyama T, Ahmed S, Suenaga A, Otagiri M. Interactions of aldosterone antagonist diuretics with human serum proteins. Pharmaceutical Research. April 1997. doi:10.1023/A:1012168020545 · PMID 9144743
238. Journal / agency Rifka SM, Pita JC, Vigersky RA, Wilson YA, Loriaux DL. Interaction of digitalis and spironolactone with human sex steroid receptors. The Journal of Clinical Endocrinology and Metabolism. February 1978. doi:10.1210/jcem-46-2-338 · PMID 86546
239. Journal / agency Pugeat MM, Dunn JF, Nisula BC. Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. The Journal of Clinical Endocrinology and Metabolism. July 1981. doi:10.1210/jcem-53-1-69 · PMID 7195405
240. Journal / agency Kaulhausen H, Rohner HG, Siedek M, Lafosse M, Breuer H. Binding capacity of sex hormone binding globulin and corticosteroid-binding globulin in serum of male patients with liver cirrhosis (author's transl). Journal of Clinical Chemistry and Clinical Biochemistry. Zeitschrift für Klinische Chemie und Klinische Biochemie. February 1980. PMID 7189544
241. Other Bland KI, Copeland III EM. The Breast: Comprehensive Management of Benign and Malignant Diseases. 9 September 2009
242. Journal / agency Murck H, Büttner M, Kircher T, Konrad C. Genetic, molecular and clinical determinants for the involvement of aldosterone and its receptors in major depression. Nephron. Physiology. 2014. doi:10.1159/000368265 · PMID 25376974
243. Journal / agency Künzel HE. Psychopathological symptoms in patients with primary hyperaldosteronism--possible pathways. Hormone and Metabolic Research = Hormon- und Stoffwechselforschung = Hormones et Metabolisme. March 2012. doi:10.1055/s-0032-1301921 · PMID 22351473
244. Journal / agency Agusti G, Bourgeois S, Cartiser N, Fessi H, Le Borgne M, Lomberget T. A safe and practical method for the preparation of 7α-thioether and thioester derivatives of spironolactone. Steroids. January 2013. doi:10.1016/j.steroids.2012.09.005 · PMID 23063964
245. Other Oxford Textbook of Medicine: Vol. 1. 2003
246. Other Szasz G, Budvari-Barany Z. Pharmaceutical Chemistry of Antihypertensive Agents. 19 December 1990
247. Other Anzenbacher P, Zanger UM. Metabolism of Drugs and Other Xenobiotics. 23 February 2012
248. Other Smith BT, Seaward BL, Smith BT. Pharmacology for Nurses. 1 November 2014
249. Other Klaassen CD. Casarett & Doull's Toxicology: The Basic Science of Poisons, Seventh Edition. 11 December 2007
250. Other Ortiz de Montellano PR. Cytochrome P450: Structure, Mechanism, and Biochemistry. 13 March 2015
251. Journal / agency Los LE, Pitzenberger SM, Ramjit HG, Coddington AB, Colby HD. Hepatic metabolism of spironolactone. Production of 3-hydroxy-thiomethyl metabolites. Drug Metabolism and Disposition. 1994. doi:10.1016/S0090-9556(25)08434-X · PMID 7895608
252. Other Black HR, Elliott W. Hypertension: A Companion to Braunwald's Heart Disease. 28 December 2006
253. Journal / agency Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedeberg's Archives of Pharmacology. January 2004. doi:10.1007/s00210-003-0833-1 · PMID 14579013
254. Other Advances in Clinical Chemistry. 31 December 2012
255. Other Brittain HG. Analytical Profiles of Drug Substances and Excipients. 26 November 2002
256. Other Benign Prostatic Hypertrophy. 6 December 2012
257. Journal / agency Matzkin H, Braf Z. Endocrine treatment of benign prostatic hypertrophy: current concepts. Urology. January 1991. doi:10.1016/0090-4295(91)80069-j · PMID 1702565
258. Journal / agency Castro JE, Griffiths HJ, Edwards DE. A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy. The British Journal of Surgery. July 1971. doi:10.1002/bjs.1800580703 · PMID 4104441
259. Journal / agency Scott WW, Menon M, Walsh PC. Hormonal Therapy of Prostatic Cancer. Cancer. April 1980. doi:10.1002/cncr.1980.45.s7.1929 · PMID 29603164
260. Journal / agency Smith JA. New methods of endocrine management of prostatic cancer. The Journal of Urology. January 1987. doi:10.1016/S0022-5347(17)43855-9 · PMID 3540320
261. Journal / agency Verma D, Thompson J, Swaminathan S. Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function. Proceedings of the National Academy of Sciences of the United States of America. March 2016. doi:10.1073/pnas.1523686113 · PMID 26976570 · PMC4822607
262. Journal / agency Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. Journal of the American Academy of Dermatology. October 2004. doi:10.1016/j.jaad.2004.03.033 · PMID 15389184
263. Journal / agency Merticariu A, Marinescu L, Giurcăneanu C. Rosacea and its comorbidities. Journal of Translational Medicine and Research. 2016. doi:10.21614/jtmr-21-1-68
264. Journal / agency Wollina U. Pathogenesis and Treatment of Acne and Rosacea. 2014. doi:10.1007/978-3-540-69375-8_95
265. Journal / agency Spoendlin J, Voegel JJ, Jick SS, Meier CR. Spironolactone may reduce the risk of incident rosacea. The Journal of Investigative Dermatology. October 2013. doi:10.1038/jid.2013.186 · PMID 23594595
266. Journal / agency Wernze H, Herdegen T. Long-term efficacy of spironolactone on pain, mood, and quality of life in women with fibromyalgia: An observational case series. Scandinavian Journal of Pain. April 2014. doi:10.1016/j.sjpain.2013.12.003 · PMID 29913681
267. Journal / agency Kalso E. From patient observation to potential new therapies-Is old spironolactone a new analgesic?. Scandinavian Journal of Pain. April 2014. doi:10.1016/j.sjpain.2014.02.006 · PMID 29913669
268. Journal / agency McElroy SL, Guerdjikova AI, Mori N, O'Melia AM. Current pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opinion on Pharmacotherapy. October 2012. doi:10.1517/14656566.2012.721781 · PMID 22946772
269. Other Jameson JL, De Groot LJ. Endocrinology - E-Book: Adult and Pediatric. 18 May 2010
270. Journal / agency Kagawa CM, Cella JA, Van Arman CG. Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science. November 1957. doi:10.1126/science.126.3281.1015 · PMID 13486053
271. Journal / agency Liddle GW. Sodium diuresis induced by steroidal antagonists of aldosterone. Science. November 1957. doi:10.1126/science.126.3281.1016 · PMID 13486054
272. Other Engel J, Kleemann A, Kutscher B, Reichert D. Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. 14 May 2014
273. Other Landau R, Achilladelis B, Scriabine A. Pharmaceutical Innovation: Revolutionizing Human Health. 1999
274. Other Jugdutt BI. Aging and Heart Failure: Mechanisms and Management. 19 February 2014
275. Journal / agency Smith WG. Spironolactone and gynaecomastia. The Lancet. 1962. doi:10.1016/S0140-6736(62)90668-2
276. Journal / agency Steelman SL, Brooks JR, Morgan ER, Patanelli DJ. Anti-androgenic activity of spironolactone. Steroids. October 1969. doi:10.1016/s0039-128x(69)80007-3 · PMID 5344274
277. Journal / agency Stewart ME, Pochi PE. Antiandrogens and the skin. International Journal of Dermatology. April 1978. doi:10.1111/j.1365-4362.1978.tb06057.x · PMID 148431
278. Journal / agency Neill JD, Johansson ED, Datta JK, Knobil, E. Endocrinology: Relationship Between the Plasma Levels of Luteinizing Hormone and Progesterone During the Normal Menstrual Cycle. Obstetrical & Gynecological Survey. 1968. doi:10.1097/00006254-196803000-00006
279. Journal / agency Tindall DJ, Chang CH, Lobl TJ, Cunningham GR. Androgen antagonists in androgen target tissues. Pharmacology & Therapeutics. 1984. doi:10.1016/0163-7258(84)90010-X · PMID 6205409
280. Journal / agency Ober KP, Hennessy JF. Spironolactone therapy for hirsutism in a hyperandrogenic woman. Annals of Internal Medicine. November 1978. doi:10.7326/0003-4819-89-5-643 · PMID 717935
281. Journal / agency Boisselle A, Tremblay RR. New therapeutic approach to the hirsute patient. Fertility and Sterility. September 1979. doi:10.1016/s0015-0282(16)44232-9 · PMID 488407
282. Journal / agency Shapiro G, Evron S. A novel use of spironolactone: treatment of hirsutism. The Journal of Clinical Endocrinology and Metabolism. September 1980. doi:10.1210/jcem-51-3-429 · PMID 7410528
283. Other Curtis M. Glass' Office Gynecology. 2014
284. Other Shah D, Bhathena RK, Shroff S. The Polycystic Ovary Syndrome. 2004
285. Other Hillard PJ. Practical Pediatric and Adolescent Gynecology. 29 March 2013
286. Journal / agency Dahl M, Feldman JL, Goldberg JM, Jaberi A. Physical Aspects of Transgender Endocrine Therapy. International Journal of Transgenderism. 2006. doi:10.1300/J485v09n03_06
287. Journal / agency Prior JC, Vigna YM, Watson D, Diewold P, Robinow O. Spironolactone in the presurgical therapy of male to female transsexuals: Philosophy and experience of the Vancouver Gender Dysphoria Clinic. Journal of Sex Information & Education Council of Canada
288. Journal / agency Fisher AD, Maggi M. Management of Gender Dysphoria. 2015. doi:10.1007/978-88-470-5696-1_10
289. Other Dorfman RI. Steroidal Activity in Experimental Animals and Man. 5 December 2016
290. Other Gláz E, Vecsei P. Aldosterone: International Series of Monographs in Pure and Applied Biology. 11 January 2017
291. Other Elks J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014
292. Other Morton IK, Hall JM. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 31 October 1999
293. Other Cardalis 5 mg/40 mg chewable tablets for Dogs (Canada). 27 August 2025

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.